Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Nottingham Advisors Inc.

Key Points

• Nottingham Advisors Inc. significantly reduced its holdings in Ocular Therapeutix by 66.2% in the first quarter, bringing their position to 33,083 shares valued at $242,000.
• A range of institutional investors have also changed their positions, with Peregrine Capital Management LLC acquiring a new position worth $6.2 million, while Deltec Asset Management LLC increased its holdings by 3.8%.
• Ocular Therapeutix has a market cap of $1.95 billion and recently received positive ratings from multiple analysts, with a consensus price target of $17.33.

Nottingham Advisors Inc. lowered its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 66.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 33,083 shares of the biopharmaceutical company's stock after selling 64,745 shares during the quarter. Nottingham Advisors Inc.'s holdings in Ocular Therapeutix were worth $242,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. MetLife Investment Management LLC grew its position in shares of Ocular Therapeutix by 2.7% during the 4th quarter. MetLife Investment Management LLC now owns 92,734 shares of the biopharmaceutical company's stock worth $792,000 after buying an additional 2,454 shares in the last quarter. Teacher Retirement System of Texas grew its position in shares of Ocular Therapeutix by 10.0% during the 4th quarter. Teacher Retirement System of Texas now owns 27,777 shares of the biopharmaceutical company's stock worth $237,000 after buying an additional 2,526 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Ocular Therapeutix by 3.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,463 shares of the biopharmaceutical company's stock worth $755,000 after buying an additional 2,853 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Ocular Therapeutix during the 4th quarter worth $28,000. Finally, Cetera Investment Advisers grew its position in shares of Ocular Therapeutix by 0.6% during the 4th quarter. Cetera Investment Advisers now owns 723,840 shares of the biopharmaceutical company's stock worth $6,182,000 after buying an additional 4,342 shares in the last quarter. Institutional investors own 59.21% of the company's stock.

Insider Buying and Selling

In other news, insider Pravin Dugel sold 21,219 shares of the stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the transaction, the insider directly owned 3,499,099 shares of the company's stock, valued at approximately $25,123,530.82. This represents a 0.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Richard L. Md Lindstrom acquired 10,000 shares of the company's stock in a transaction that occurred on Thursday, May 8th. The stock was purchased at an average cost of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director directly owned 172,704 shares in the company, valued at $1,202,019.84. This represents a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 29,079 shares of company stock valued at $208,739. Company insiders own 2.30% of the company's stock.

Ocular Therapeutix Stock Performance

OCUL traded down $0.10 on Thursday, hitting $11.56. 828,240 shares of the company traded hands, compared to its average volume of 1,752,450. The company has a 50 day moving average of $9.53 and a 200-day moving average of $8.18. The company has a quick ratio of 10.14, a current ratio of 10.22 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $1.84 billion, a PE ratio of -10.04 and a beta of 1.43. Ocular Therapeutix, Inc. has a 12-month low of $5.78 and a 12-month high of $12.35.

Analyst Ratings Changes

OCUL has been the subject of a number of analyst reports. William Blair initiated coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating for the company. Needham & Company LLC decreased their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Finally, HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Ocular Therapeutix has a consensus rating of "Buy" and an average target price of $17.33.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.